Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRL2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,730
Award facts
- Contract value 100% obligated
- $24,729.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24,729.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for supply of Jakafi 10 mg tablets (60-count units). The delivery order, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion enterprise-wide acquisition strategy designed to streamline pharmaceutical procurement for the Department of Defense.
The PPV-G GEN V program establishes regional prime vendor contracts to supply a comprehensive range of pharmaceutical products, including branded and generic medications, biologics, vaccines, and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's prime vendor contract, awarded November 13, 2025, features a $499,999,999 ceiling and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month periods. The company's established performance across multiple delivery orders and its competitive capability in unrestricted federal procurement demonstrate its readiness to fulfill the specialized pharmaceutical requirements of the Department of Defense military medical system without reliance on subcontractors.
Quick answers
Who was awarded contract SPE2DR26FCRL2?
SPE2DR26FCRL2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FCRL2 worth?
The government has obligated $24,730 on SPE2DR26FCRL2.
Is contract SPE2DR26FCRL2 an order under another contract?
Yes. SPE2DR26FCRL2 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRL2 competed?
The extent of competition for SPE2DR26FCRL2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award